Matinas BioPharma Holdings Inc (MTNB) — Cash Flow-to-Debt Ratio
Matinas BioPharma Holdings Inc (MTNB) has a Cash Flow-to-Debt Ratio of -0.56x as of March 2026, meaning its operating cash flow of $-1.60 Million could theoretically repay -1% of its total liabilities ($2.85 Million) in one year. Explore Matinas BioPharma Holdings Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Matinas BioPharma Holdings Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Matinas BioPharma Holdings Inc across 14 annual periods. Also explore MTNB total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Matinas BioPharma Holdings Inc (2012–2025)
Year-by-year debt coverage analysis for Matinas BioPharma Holdings Inc. For market capitalisation and broader financial context, see MTNB market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.95x | $-7.01 Million | $2.38 Million | ▲ +6.3% |
| 2024 | -3.14x | $-15.88 Million | $5.05 Million | ▼ -20.6% |
| 2023 | -2.61x | $-15.28 Million | $5.86 Million | ▼ -474.9% |
| 2022 | -0.45x | $-19.16 Million | $42.23 Million | ▲ +73.7% |
| 2021 | -1.72x | $-15.22 Million | $8.83 Million | ▲ +28.2% |
| 2020 | -2.40x | $-17.37 Million | $7.24 Million | ▼ -22.4% |
| 2019 | -1.96x | $-14.09 Million | $7.19 Million | ▲ +27.8% |
| 2018 | -2.72x | $-10.32 Million | $3.80 Million | ▲ +11.3% |
| 2017 | -3.06x | $-11.46 Million | $3.74 Million | ▼ -33.5% |
| 2016 | -2.29x | $-6.12 Million | $2.67 Million | ▲ +31.5% |
| 2015 | -3.35x | $-7.81 Million | $2.33 Million | ▲ +52.3% |
| 2014 | -7.02x | $-7.96 Million | $1.13 Million | ▼ -101.9% |
| 2013 | -3.48x | $-2.99 Million | $858.97K | ▼ -412.8% |
| 2012 | -0.68x | $-57.26K | $84.43K | — |